Last reviewed · How we verify
Inhaled nebulized salbutamol.
At a glance
| Generic name | Inhaled nebulized salbutamol. |
|---|---|
| Also known as | Farcoline respirator 0,5% solution. |
| Sponsor | Assiut University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nasopharyngitis
- Upper Respiratory Tract Infection
- Rhinitis Allergic
- Bronchitis
- Pharyngitis
- Injection Site Erythema
- Viral Upper Respiratory Tract Infection
- Influenza
- Headache
- Cough
- Injection Site Oedema
- Sinusitis
Key clinical trials
- Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis (PHASE1, PHASE2)
- The Effect of NAC on Lung Function and CT Mucus Score (PHASE4)
- Randomized Controlled Trial Comparing Standard Versus Positive Pressure Nebulization in Infants With Bronchiolitis to Reduce Hospital Admissions (NA)
- the Inhaled β2-adrenergic Receptor Agonist for Transient Tachypnoea of the Newborn (the REFSAL Trial) (PHASE3)
- BiPAP in Pediatric Moderate to Severe Asthma Randomized Control Trial (NA)
- Bronchodilators and Lung Mechanics During Exercise in COPD (PHASE4)
- Physiological Effects of Nebulized Salbutamol in Acute Respiratory Failure Patients on HFNC (PHASE2, PHASE3)
- Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inhaled nebulized salbutamol. CI brief — competitive landscape report
- Inhaled nebulized salbutamol. updates RSS · CI watch RSS
- Assiut University portfolio CI